Xanodyne Pharmaceuticals Inc., a Florence, Ky.-based drug company, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol XANO, with Morgan Stanley and Deutsche Bank Securities serving as co-ead underwriters.
The company has raised around $232 million in total VC funding, including a $170 million Series A-1 round in 2005 that helped finance the $210 million acquisition of aaiPharma’s pharmaceutical division out of bankruptcy.
Shareholders include Apax Partners (23.2% pre-IPO stake), MPM Capital (21.3%), AIG (10.9%), Essex Woodlands Health Ventures (10.7%), HealthCare Ventures (10.3%), Aisling Capital (9.5%) and Blue Chip Venture Co. (7.8%). www.xanodyne.com